Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.70 |
| ▸ | CNR2 | P34972 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10256809 | 0.88 | CNR1 (0.54) | CNR1CNR2LMNATAS1R3TAS1R1 | |
| SCHEMBL6515255 | 0.83 | CNR1 (1.00) | CNR1CNR2LMNATAS1R3TAS1R1 | |
| SCHEMBL3390949 | 0.83 | CNR1 (1.00) | CNR1CNR2LMNATAS1R3TAS1R1 | |
| SCHEMBL10246997 | 0.80 | LMNA (0.62) | LMNATAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL10247155 | 0.78 | LMNA (0.77) | LMNATAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL10247010 | 0.76 | HDAC3 (0.54) | CNR1CNR2LMNATAS1R3TAS1R1 | |
| SCHEMBL10246865 | 0.76 | LMNA (0.54) | LMNATAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL10247153 | 0.76 | LMNA (0.50) | LMNATAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL10246849 | 0.75 | TAS1R3 (0.50) | LMNATAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL10246948 | 0.75 | PRSS12 (0.65) | LMNATAS1R3TAS1R1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | CNR1 2818/4885CNR2 1904/4885LMNA 1529/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | CNR1 1527/4885CNR2 887/4885LMNA 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.